Similarly, the time course showed that RT-PCR from pharyngeal swab resulted negative in an average time of 3 days after therapy start, while RT-PCRs from bronchoalveolar lavage continued to permit infection monitoring and therapy regimen conduction.
Similarly, the time course showed that RT-PCR from pharyngeal swab resulted negative in an average time of 3 days after therapy start.
The average time of beginning the Rotoprone®-therapy was on the 8.8th day (2/21), the average time of respiratory support was 33.4th day (18/59).
Those who were switched to Vigabatrin after prior ACTH therapy relapsed after 6 months on average as opposed to those who were switched to ACTH therapy after prior Vigabatrin therapy, who relapsed after an average time of 2 months.
First, although our image-registration process takes an average time of <10 min, additional time was required to manually contour the lesion and prostatic capsule on MR-images, and to pre-process the MRI data before therapy.
The average time under prophylactic therapy at inclusion was 3.2 months (2 patients were under preventive therapy for 2 months, the other 3 for 4 months).
Average time to initiation of appropriate antibiotic therapy was 9 ± 23 hours.
In our population, the average time from initiation of anti-TNF therapy to clinical infection was > 15 months, making reactivation a less likely mode of acquisition of disease.
The average time from the initiation of biological agent therapy to development of NTM was 10 months (range: 6 weeks to 8.5 years), similar to our case (15 months).
